Subscribe To

Price Alert Latest News Economic Calendar News

BIOVF / Swedish Orphan Biovitrum AB (BIOVF) CEO Guido Oelkers on Q1 2022 Results - Earnings Call Transcript

Swedish Orphan Biovitrum AB (OTCPK:BIOVF) Q1 2022 Earnings Conference Call April 28, 2022 7:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financial Officer Anders Ullman - Head of Research & Development, Chief Medical Officer Armin Reininger - Head of Medical and Scientific Affairs Conference Call Participants Adam Karlsson - ABG Viktor Sundberg - Nordea Peter Östling - Pareto Securities Christopher Uhde - SEB Mattias Häggblom - Handelsbanken Erik Hultgård - Carnegie Adam Karlsson - ABG Eun Yang - Jefferies Christopher Uhde - SEB Caroline Banér - Danske Bank Viktor Sundberg - Nordea Operator Ladies and gentlemen, welcome to the Sobi Q1 2022 report. Throughout the call, all participants will be in a listen-only mode. Read More

Demo Live Account See Partner Details

Content Topics

Swedish

Orphan

Biovitrum

BIOVF

Guido

Oelkers

2022

Results

biovf

Earnings

Transcript

Stock

Posted: Apr 30 2022, 06:19

Author Name: Seeking Alpha

BIOVF News

By Seeking Alpha
October 30, 2023

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2023 Earnings Call Transcript

By Zacks Investment Research
October 30, 2023

Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss Estimates

Swedish Orphan Biovitrum (BIOVF) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.09 per share. This co

By Zacks Investment Research
August 29, 2023

Is Swedish Orphan Biovitrum (BIOVF) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Neverthe

By Zacks Investment Research
July 18, 2023

Swedish Orphan Biovitrum (BIOVF) Beats Q2 Earnings and Revenue Estimates

Swedish Orphan Biovitrum (BIOVF) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This co

By Seeking Alpha
April 29, 2023

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2023 Earnings Call Transcript

Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q1 2023 Earnings Conference Call April 27, 2023 8:00 AM ET Company Participants Guido Oelkers - Chief

By Zacks Investment Research
April 27, 2023

Swedish Orphan Biovitrum (BIOVF) Q1 Earnings and Revenues Beat Estimates

Swedish Orphan Biovitrum (BIOVF) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.22 per share. This co

By Seeking Alpha
February 8, 2023

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2022 Earnings Call Transcript

Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q4 2022 Results Conference Call February 8, 2023 7:00 AM ET Company Participants Guido Oelkers - CEO

By Seeking Alpha
April 30, 2022

Swedish Orphan Biovitrum AB (BIOVF) CEO Guido Oelkers on Q1 2022 Results - Earnings Call Transcript

Swedish Orphan Biovitrum AB (OTCPK:BIOVF) Q1 2022 Earnings Conference Call April 28, 2022 7:00 AM ET Company Participants Guido Oelkers - Chief Execut

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.